Next-generation SERD therapy with promising results

The results of the Phase III EMBER-3 trial of imlunestrant, a next-generation oral selective oestrogen receptor degrader (SERD) for patients with hormone receptor-positive breast cancer in ER-positive, HER2-negative advanced breast cancer (ABC), were presented at the SABCS. The study shows that patients with an ESR1 mutation in particular benefit.